Indication
Hemophilic Pseudotumor
1 clinical trial
1 product
Clinical trial
Prospective, Single-arm, Open-label Use of Hemlibra (Emicizumab) to Treat Hemophilic PseudotumorStatus: Terminated, Estimated PCD: 2022-03-16
Product
Emicizumab1 clinical trial
1 product